A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

The study will be conducted in patients with metastatic colorectal cancer (mCRC) harboring a BRAFV600E mutation, to collect clinical data and biological samples to be used for research but also to gather real-world clinical data concerning the treatments and the survival outcomes in patients with this pathology.

Inclusion Criteria:Adults aged 18 years or olderHistologically confirmed BRAFV600E metastatic colorectal cancer (mCRC), chemotherapy-naive in the metastatic settingAvailable tumor tissue sample obtained less than 2 months before inclusion (if older tumoral tissue samples are available, these will also be collected) with sufficient tissue left for biological studies. Patients with only fine-needle aspirations (FNA) are not eligible.Known MMR deficiency/microsatellite status (IHC and PCR) (or under analysis)Signed informed consentPatients must be willing and able to comply with the study proceduresThe patient must be affiliated to a social security system or equivalent.Exclusion Criteria:Patient with another cancer concomitantly with the mCRC requiring treatment or influencing the prognosis according to the medical staff.Patients for whom the follow-up won't be assured by the investigator or its team.Persons deprived of their liberty or under protective custody or guardianship.